Skip to main content
OpenTrials
Completed

NCT Number: NCT01169272

Clinical Evaluation Of The SonR Atrial Lead In Paradym RF Device

Sorin Group has developed a new atrial lead which is under evaluation during this study. The SonR atrial lead presents a new sensor in the tip of the lead and allows a new feature; interventricular (VV) and atrioventricular (AV) delay (VVD and AVD) optimization.

The new RV autothreshold algorithm has been implemented in the CRT-ICD and will help the physician in his diagnosis avoiding potential lost of capture.

The ICD device has also the capability to be remotely interrogated through the remote monitoring system whose performances will be reported during the study.

Finally, the study will report the electrical and handling performances of the new left ventricular lead.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Leclercq

Rennes, 35033, France

About this study

In this study, the sponsor aims at:

  • Demonstrating the safety of the atrial SonR lead;
  • Demonstrating the performances of the right ventricular autothreshold algorithm ;
  • Reporting the adverse events documented in the study;
  • Reporting electrical performances of Sorin Group PARADYM ICD, in order to validate that the performances of those devices are in conformance with longevity and effectiveness objectives;
  • Reporting the Sorin atrial SonR and Situs 2 MV left ventricular leads performances;
  • Reporting the SonR atrial lead mechanical handling.
  • Reporting all information from SonR sensor to validate the SonR data exploitation and the AVD/VVD optimization.
  • Reporting the Situs 2 MV LV lead mechanical handling.
  • Assessing the user satisfaction (patient and physician) of the remote monitoring solution and the overall availability of the system in terms of data.

Thus, this study intends to show that PARADYM RF ICD operate safely and appropriately in intended-use as part of an ICD system.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient eligible for implantation of a CRT 9770 device accordingly to the relevant currently-approved ACC/AHA/ESC guidelines or any relevant currently approved local guidelines for the implantation or replacement of triple-chamber ICD
  • Implanted with atrial SonR lead
  • Signed and dated informed consent

Exclusion criteria

  • VT/VF is associated with drug toxicity, electrolyte imbalance, hypoxia, or other reversible cause;
  • VT/VF occurred during the acute phase of infarction (< 3 weeks) or during an unstable ischemic phase;
  • VF was caused by electrocution;
  • Incessant VT/VF;
  • Patient is unable to attend the scheduled follow-ups at the implanting centre;
  • Patient is already enrolled in another ongoing clinical study;
  • Patient is unable to understand the aim of the study and its procedure;
  • Patient refuses to cooperate;
  • Patient is unable or refuses to provide informed consent;
  • Patient is minor (less than 18-year old);
  • Patient is pregnant;
  • Patient has life expectancy of less than 1 year;
  • Patient is forfeiture of freedom or under guardianship.

Treatment and study plan

CRT-SonR 9770

Device

Active implantable defibrillator with capacity of cardiac resynchronization therapy

Other names: 9770

Primary outcomes

  1. Evaluation of the SonR lead safety

    Time frame: 3 months

    Complication free rate of the SonR lead superior to 90 %

Secondary outcomes

  1. Incidence of adverse events

    Time frame: 12 months

    Any adverse will be documented thoughout the study and will be reported.

  2. ICD electrical performances

    Time frame: 12 months

    Report all ICD electrical performances of the Paradym RF ICD

  3. Evaluation of the SonR atrial lead performance

    Time frame: 3 months

    Report electrical performances and lead handling at implant

  4. Evaluation of the AV/VV delays optimization

    Time frame: 3 months

    Describe the performances of the manual and automatic AV/VV optimization algorithms. An optional daily life test could be performed to evaluate the automatic optimization at exercise.

  5. Evaluation of the left ventricular lead performances

    Time frame: 12 months

    Report the electrical performances and lead mechanical handling at implant.

  6. Evaluation of the Remote Monitoring Solution

    Time frame: 12 months

    Ensure the Home Monitor setup procedure and daily life use are user friendly for the patient and the back office is convenient for the physician.

  7. Evaluation of the right ventricular autothreshold performances

    Time frame: 1 month

    Demonstrate that the automatic RV pacing thresholds measures are equivalent to the manual test with an authorized error of 0,25V.

Sponsors and collaborators

Lead sponsor

LivaNova

Industry

Registry information

Official study title

Clinical Evaluation Of SonR Atrial Lead In Paradym RF Device SORIN GROUP'S New ICD Plateform

Important dates

Study start
2010
Primary completion
2011
Study completion
2012
First posted
Jul 26, 2010
Registry last updated
Jun 18, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.